MAPT and Alzheimer disease: Recent studies have highlighted the potential of specific plasma biomarkers—including amyloid beta (Aβ42, Aβ42/40), phosphorylated-tau proteins (p-tau181, p-tau217, p-tau231), and neurofilament light chain (NfL), all of which are closely associated with AD-related neuropathological changes [15].